Wednesday October 31, 4:10 pm ET CC
Press Release
SOURCE: Human Genome Sciences, Inc.
Human Genome Sciences Will Sponsor Conference Call
ROCKVILLE, Md., Oct. 31 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - news) announced today that it will sponsor a conference call for analysts and investors to discuss an announcement to be made in a press conference tomorrow morning.
(Photo: newscom.com )
The conference call will be hosted by senior management and will be held on Thursday, November 1, 2001, at 4:15 p.m. Eastern.
Investors may listen to the call by dialing 719-457-2657 or 800-946-0782, meeting number 432017, five to ten minutes before the start of the call. A replay of the conference call will be available for several days by dialing 719-457-0820 or 888-203-1112, meeting number 432017. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit the Human Genome Sciences website at hgsi.com . The archive of the conference call will be available approximately two hours after the conference call and will be available for several days.
Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients.
HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc. For additional information on Human Genome Sciences, Inc., visit the company's web site at hgsi.com . Copies of HGS press releases are also available by fax 24 hours a day at no charge by calling 800-758-5804, ext. 121115.
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, dependence on new technologies, uncertainty and timing of clinical trials, ability to develop and commercialize products, dependence on collaborators for services and revenue, substantial indebtedness, intense competition, uncertainty of patent and intellectual property protection, dependence on key management, uncertainty of regulation of products, dependence on key suppliers, the impact of future alliances or transactions and other risks that may be described in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.
SOURCE: Human Genome Sciences, Inc. |
